Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Cash from Financing Activities (2016 - 2021)

GT Biopharma (GTBP) has disclosed Cash from Financing Activities for 12 consecutive years, with $137000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Cash from Financing Activities fell 88.58% to $137000.0 in Q3 2021 year-over-year; TTM through Dec 2021 was $42.3 million, a 237.7% increase, with the full-year FY2025 number at $15.8 million, up 430.07% from a year prior.
  • Cash from Financing Activities was $137000.0 for Q3 2021 at GT Biopharma, down from $16.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $25.9 million in Q1 2021 to a low of $137000.0 in Q3 2021.
  • A 5-year average of $4.7 million and a median of $1.2 million in 2020 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 12871.0% in 2021; the steepest drop was 88.58% in 2021.
  • GT Biopharma's Cash from Financing Activities stood at $4.9 million in 2017, then surged by 32.29% to $6.5 million in 2018, then tumbled by 96.93% to $200000.0 in 2019, then soared by 3337.0% to $6.9 million in 2020, then tumbled by 98.01% to $137000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Cash from Financing Activities are $137000.0 (Q3 2021), $16.2 million (Q2 2021), and $25.9 million (Q1 2021).